Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017153955) USE OF ANTI-MCAM ANTIBODIES FOR TREATMENT OR PROPHYLAXIS OF GRANULOMATOUS LUNG DISEASES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/153955 International Application No.: PCT/IB2017/051402
Publication Date: 14.09.2017 International Filing Date: 09.03.2017
IPC:
C07K 16/30 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
PROTHENA BIOSCIENCES LIMITED [IE/IE]; Adelphi Plaza, Upper George's Street Dun Laoghaire Co. Dublin A96 T927, IE
Inventors:
FLANAGAN, Kenneth; US
HAMZEH, Nabeel; US
Priority Data:
62/306,06009.03.2016US
Title (EN) USE OF ANTI-MCAM ANTIBODIES FOR TREATMENT OR PROPHYLAXIS OF GRANULOMATOUS LUNG DISEASES
(FR) UTILISATION D'ANTICORPS ANTI-MCAM POUR LE TRAITEMENT OU LA PROPHYLAXIE DE MALADIES PULMONAIRES GRANULOMATEUSES
Abstract:
(EN) The invention provides anti-MCAM antibodies that inhibit the ability of human MCAM to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of chronic beryllium disease (CBD), Blau syndrome or hot tub lung disease, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of granulomatous lung diseases.
(FR) La présente invention concerne des anticorps anti-MCAM qui inhibent la capacité de la MCAM humaine à se lier à une chaîne alpha-4 de la laminine, ainsi que des compositions pharmaceutiques et des formulations pharmaceutiques les comprenant, destinées à être utilisées dans le traitement ou la prophylaxie de la bérylliose chronique (CBD), du syndrome de Blau ou du syndrome des jacuzzis et spas. L'invention concerne également des procédés de production de ces anticorps, et leur utilisation dans la fabrication de médicaments pour le traitement de maladies pulmonaires granulomateuses.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)